Written question asked by Jane Griffiths (Labour) on Monday, 21 March 2005, in the House of Commons. It was due for an answer on Thursday, 24 March 2005. It was answered by Baroness Winterton of Doncaster (Labour) on Thursday, 24 March 2005 on behalf of the Department of Health.
Dept of Health
- Question
- To ask the Secretary of State for Health, what assessment he has made of the measures of cost-effectiveness applied by the National Institute of Clinical Excellence in evaluating whether acetylcholinesterase inhibitors should continue to be available to treat sufferers from Alzheimer's disease; what assessment his Department has made of the effectiveness of acetylcholinesterase inhibitors in improving cognitive and global outcomes for sufferers from Alzheimer's disease.
- Answer
-
Jane Griffiths: To ask the Secretary of State for Health (1) what assessment he has made of the measures of cost- effectiveness applied by the National Institute for Clinical Excellence in evaluating whether acetylcholinesterase inhibitors should continue to be available to treat sufferers from Alzheimer's disease; [223627] (2) what assessment his Department has made of the effectiveness of acetylcholinesterase inhibitors in improving cognitive and global outcomes for sufferers from Alzheimer's disease. [223628] Ms Rosie Winterton: The National Institute for Clinical Excellence (NICE) published its draft technology appraisal guidance on drugs for Alzheimer's disease for consultation on 1 March 2005. NICE is an independent body with an internationally recognised reputation for the robustness of its technology appraisal development process. The Department responded to NICE'S consultation on the guidance on the 22 March and a copy of the response is available in the Library. NICE will be issuing a final version of this new guidance later in the year, after considering responses to its consultation. Until then, the recommendations in NICE's original 2001 appraisal continue to apply.
Secondary information
- Type
- Written question
- Reference
- 432 c1044W; 223627;223628
- Session
- 2004-05
- Subjects
- Alzheimer's disease Drugs Prescription drugs National Institute for Clinical Excellence
- Link
- View this Written question on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2013-11-24 23:30:17 +0000
- URI
- http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1032579
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1032579
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/Hansard/PARLIAMENTARY_QUESTION_1032579